Shares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab, which it was developing in partnership with Japanese pharmaceutical company Eisai.
The company said in a statement that the decision to stop the phase 3 trial is based on an independent group's analysis showing that the trials were unlikely to"meet their primary endpoint." The recommendation to stop the studies was not based on safety concerns, Biogen said. "This disappointing news confirms the complexity of treating Alzheimer's disease and the need to further advance knowledge in neuroscience," said Michel Vounatsos, chief executive officer of Biogen, in a statement."We are incredibly grateful to all the Alzheimer's disease patients, their families and the investigators who participated in the trials and contributed greatly to this research.
No quick fix for Trump
Literally no one expected it to be a blockbuster.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »